Artificial Intelligence, Data Sensors and Interconnectivity: Future Opportunities for Heart Failure

Patrik Bächtiger, Carla M. Plymen, Punam Pabari, James P. Howard, Zachary I. Whinnett, Felicia Opoku, Stephen Janering, A. Aldo Faisal, Dárrel P. Francis, Nicholas S. Peters

Abstract

A higher proportion of patients with heart failure have benefitted from a wide and expanding variety of sensor-enabled implantable devices than any other patient group. These patients can now also take advantage of the ever-increasing availability and affordability of consumer electronics. Wearable, on- and near-body sensor technologies, much like implantable devices, generate massive amounts of data. The connectivity of all these devices has created opportunities for pooling data from multiple sensors - so-called interconnectivity - and for artificial intelligence to provide new diagnostic, triage, risk-stratification and disease management insights for the delivery of better, more personalised and cost-effective healthcare. Artificial intelligence is also bringing important and previously inaccessible insights from our conventional cardiac investigations. The aim of this article is to review the convergence of artificial intelligence, sensor technologies and interconnectivity and the way in which this combination is set to change the care of patients with heart failure.

Introduction

Heart failure (HF) incidence and prevalence are rising globally, placing an immense burden on healthcare systems. While clinicians currently have access to a vast array of management tools—from advanced pacemakers to consumer smartwatches—they are increasingly facing a "data-rich, insight-poor" dilemma. The core challenge lies in data silos where information is trapped in proprietary systems, high false-positive rates in remote monitoring leading to "alarm fatigue," and the inherent heterogeneity of HF as a syndrome. This paper reviews how the convergence of artificial intelligence (AI), diverse sensor technologies, and high-speed interconnectivity can transform reactive medicine into a proactive "predict-and-prevent" model of personalized care.

The Sensor and Data Ecosystem

The technological landscape for HF management is built upon three primary pillars: internal sensors, external sensors, and the interconnectivity that binds them. Internal sensors include established devices like pacemakers and Cardiac Resynchronization Therapy (CRT) units, as well as specialized tools like pulmonary artery pressure (PAP) and left atrial pressure (LAP) sensors. External sensors encompass consumer electronics such as smartphones, wearables, and Internet of Things (IoT) devices like smart scales.

The ecosystem of heart failure monitoring, connecting internal and external sensors through AI-driven interconnectivity.

Interconnectivity, facilitated by cloud architecture and 5G, serves as the "glue" that allows for pooling data from these disparate sources. This holistic view enables AI to process multimodal data streams to provide real-time clinical insights.

Machine Learning Methodologies

To translate raw sensor data into actionable clinical intelligence, various machine learning (ML) techniques are employed. These range from supervised learning for specific risk predictions to unsupervised learning for identifying novel patient subgroups, a process known as phenomapping.

Key definitions of artificial intelligence and machine learning terms relevant to heart failure monitoring.

By applying these methodologies, researchers can move beyond traditional HF classifications (such as ejection fraction) to find hidden patterns in data, helping to identify which specific patients will benefit most from targeted therapies or device interventions.

Clinical Insights and Quantitative Results

One of the most transformative applications of AI in this field is the development of "bloodless blood tests." Deep learning models can now extract physiological data from standard signals that are invisible to the human eye. For instance, AI can quantify potassium levels from a standard ECG, potentially allowing patients to monitor electrolytes non-invasively at home. Furthermore, AI models can detect asymptomatic left ventricular (LV) dysfunction with high accuracy using only ECG traces, identifying at-risk patients long before clinical symptoms appear.

Quantitative successes highlighted in recent literature include:

  • Hospitalization Reduction: The use of PAP monitoring (e.g., CardioMEMS) has been shown to reduce HF-related hospital admissions by 33%.
  • High Sensitivity Triage: The Triage-HF Plus pathway achieved a 98.6% sensitivity for identifying patients at high risk of decompensation by combining device data with simple telephone triage.
  • Diagnostic Accuracy: Deep learning models have achieved approximately 86% sensitivity and specificity in detecting LV dysfunction from ECGs alone, with some studies reporting up to 100% accuracy in distinguishing healthy versus HF ECG traces using convolutional neural networks.

Challenges and Future Directions

Despite the significant promise of AI-integrated care, several hurdles remain. The "black box" nature of many ML models limits clinician trust due to a lack of interpretability. Additionally, algorithmic bias can emerge if training datasets are not representative of diverse populations. Data privacy, ownership, and the proprietary nature of device data also present significant legal and ethical obstacles.

The authors conclude that the next decade will be defined by the frontline implementation of these technologies. Success will require a human-centric approach that empowers both patients and providers, moving toward a "closed-feedback loop" where AI offers autonomous decision support—such as suggesting diuretic dose adjustments—under careful clinician oversight.

Summary updated

Abstract

A higher proportion of patients with heart failure have benefitted from a wide and expanding variety of sensor-enabled implantable devices than any other patient group. These patients can now also take advantage of the ever-increasing availability and affordability of consumer electronics. Wearable, on- and near-body sensor technologies, much like implantable devices, generate massive amounts of data. The connectivity of all these devices has created opportunities for pooling data from multiple sensors - so-called interconnectivity - and for artificial intelligence to provide new diagnostic, triage, risk-stratification and disease management insights for the delivery of better, more personalised and cost-effective healthcare. Artificial intelligence is also bringing important and previously inaccessible insights from our conventional cardiac investigations. The aim of this article is to review the convergence of artificial intelligence, sensor technologies and interconnectivity and the way in which this combination is set to change the care of patients with heart failure.
BibTeX
@inproceedings{bachtiger2020artificial,
  author = {Patrik Bächtiger and Carla M. Plymen and Punam Pabari and James P. Howard and Zachary I. Whinnett and Felicia Opoku and Stephen Janering and A. Aldo Faisal and Dárrel P. Francis and Nicholas S. Peters},
  title = {{Artificial Intelligence, Data Sensors and Interconnectivity: Future Opportunities for Heart Failure}},
  booktitle = {Cardiac},
  year = {2020},
  doi = {10.15420/cfr.2019.14},
}
Figure